Accueil   Diary - News   All news Pragma Therapeutics

Pragma Therapeutics

Pragma Therapeutics has the French status of “Young innovative Company”, and joined the incubator Pulsalys based in Lyon last June 2015, which will provide financial support to progress its program further towards preclinical proof-of-concept. In addition, Pragma therapeutics has recently received the FrenchTech grant from BPIFrance (co-financed with the National Institute for Intellectual Property – INPI) to support patents filing and market analysis, as well as a specific scientific package. Last November 2014, Pragma Therapeutics was nominated at the Italian Venture Forum held in Turino, receiving its first award as innovative company in life science from an investor panel.




About Pragma
Pragma Therapeutics is a biopharmaceutical company, member of Lyonbiopole and located at the Biopark of Archamps Technopôle in Haute-Savoie, which was incorporated in January 2015. Its two co-founders Dr. Sylvain Celanire and Dr. Guillaume Duvey, gather more than 15 years of R&D experience each in major european pharmaceutical companies such as UCB Pharma and Janssen Pharmaceutica, as well as within the Swiss biotech Addex Therapeutics. Pragma Therapeutics focuses on the discovery and development of small molecule therapeutics acting at a brain-specific protein localised in discrete regions involved in the regulation of stress. Their peculiar mechanism of action, called « allosteric modulation », allows a unique and innovative treatment of severe neurological and psychiatric disorders, in particular acute and chronic stress such as Post-Traumatic Stress Disorders (PTSD). The first molecules identified from its discovery platform already demonstrated a selective and specific biological activity at the therapeutic target, as well as brain penetration allowing moving forward the lead molecule in animal models of acute stress.

More information :